Canada - English - Health Canada

stallergenes canada inc - grass pollen allergen extract - tablet - 300unit - grass pollen allergen extract 300unit - allergenic extracts

New Zealand - English - Medsafe (Medicines Safety Authority)

stallergenes greer new zealand ltd - grass pollen extract 100 ir; allergen extracts 300 ir (grass pollen) - sublingual tablet - active: grass pollen extract 100 ir excipient: colloidal silicon dioxide croscarmellose sodium lactose magnesium stearate microcrystalline cellulose active: allergen extracts 300 ir (grass pollen) excipient: colloidal silicon dioxide croscarmellose sodium lactose magnesium stearate microcrystalline cellulose - treatment of grass pollen allergic rhinitis with or without conjunctivitis in adults, adolescents and children (above the age of 5) with clinically relevant symptoms, confirmed by a positive cutaneous test and/or a positive titre of the specific ige to the grass pollen.

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

dermcare-vet pty. ltd. - allergenic extract - parenteral liquid/solution/suspension - allergenic extract ungrouped active 0.0 p - diagnostic agents - dog | bitch | castrate | puppy - diagnostic agent | allergy screen test | intradermal test | johne's diseases diagnosis | tuberculin test | tuberculosis detection

Australia - English - Department of Health (Therapeutic Goods Administration)

stallergenes australia pty ltd - poa pratensis, quantity: 20 %; anthoxanthum odoratum, quantity: 20 %; phleum pratense, quantity: 20 %; dactylis glomerata, quantity: 20 %; lolium perenne, quantity: 20 % - tablet - excipient ingredients: microcrystalline cellulose; croscarmellose sodium; magnesium stearate; colloidal anhydrous silica; lactose monohydrate - treatment of grass pollen allergic rhinitis with or without conjunctivitis in adults, adolescents and children (above the age of 5) with clinically relevant symptoms, confirmed by a positive cutaneous test and/or a positive titre of the specific ige to the grass pollen.

Australia - English - Department of Health (Therapeutic Goods Administration)

stallergenes australia pty ltd - lolium perenne, quantity: 20 %; phleum pratense, quantity: 20 %; anthoxanthum odoratum, quantity: 20 %; dactylis glomerata, quantity: 20 %; poa pratensis, quantity: 20 % - tablet - excipient ingredients: croscarmellose sodium; colloidal anhydrous silica; magnesium stearate; microcrystalline cellulose; lactose monohydrate - treatment of grass pollen allergic rhinitis with or without conjunctivitis in adults, adolescents and children (above the age of 5) with clinically relevant symptoms, confirmed by a positive cutaneous test and/or a positive titre of the specific ige to the grass pollen.

New Zealand - English - Medsafe (Medicines Safety Authority)

ebos group ltd - allergen extracts 10 ic/ml (chicken (33%), duck (33%), goose (33%) feathers extract) - solution for injection - 10 ic/ml - active: allergen extracts 10 ic/ml (chicken (33%), duck (33%), goose (33%) feathers extract) excipient: aluminium hydroxide gel mannitol phenol sodium chloride water

New Zealand - English - Medsafe (Medicines Safety Authority)

ebos group ltd - allergen extracts 10 ic/ml (equine epithelium extract) - solution for injection - 10 ic/ml - active: allergen extracts 10 ic/ml (equine epithelium extract) excipient: aluminium hydroxide gel mannitol phenol sodium chloride water

New Zealand - English - Medsafe (Medicines Safety Authority)

ebos group ltd - allergen extracts 10 ic/ml (rumex acetosa pollen extract) - solution for injection - 10 ic/ml - active: allergen extracts 10 ic/ml (rumex acetosa pollen extract) excipient: aluminium hydroxide gel mannitol phenol sodium chloride water

New Zealand - English - Medsafe (Medicines Safety Authority)

seqirus (nz) ltd - dermatophagoides farinae allergen extract 6 sq-hdm; dermatophagoides pteronyssinus allergen extract 6 sq-hdm - sublingual tablet - 12 sq-hdm - active: dermatophagoides farinae allergen extract 6 sq-hdm dermatophagoides pteronyssinus allergen extract 6 sq-hdm excipient: gelatin mannitol sodium hydroxide - acarizax is indicated for the treatment of adults diagnosed with: - house dust mite (hdm) allergic rhinitis (ar) not well controlled despite use of symptom relieving medication or - hdm allergic asthma (aa) not well controlled by inhaled corticosteroids and associated with hdm allergic rhinitis. patients' asthma status should be carefully evaluated before the initiation of treatment.

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

stallergens, france - allergen extract "animal origin initial" - solution - 100 mg/ml